Introduction
Gastric cancer (GC) ranks among the top four cancer diagnoses and is the second most common cause of cancer-related death in the world. [1] [2] [3] In spite of advances made in the early detection and treatment of GC, 4, 5 it is frequently not diagnosed until an advanced stage, and has a low survival rate. [6] [7] [8] The main risk factors for gastric cancer include Helicobacter pylori (H pylori) infection and dietary factors. 9, 10 Beside environmental factors, GC is a complicated multistep process involving various oncogenic signaling pathways. 11, 12 Until now, due to its high incidence rate, poor prognosis, and limited treatment options, GC remains a major clinical challenge to clinicians.
Rhotekin (RTKN) has been identified as a Rho effector protein. Rho is one of the best-characterized members of Rho GTPases, which play a critical role in multiple biological processes, including cytoskeleton reorganization, cell differentiation, cell cycle progression, and cell migration. 13 RTKN was initially found complexing with active form of Rho, 14 and subsequent studies identified several interaction partners of RTKN, 20 and S100A4, 21 and suggested possible functions of RTKN in the formation and/or maintenance of septin filament, focal adhesions, stress fiber, and cell polarity. Evidence has suggested that RTKN is overexpressed in human cancer tissues, including GC 22 and bladder cancer, 23 when compared with corresponding normal tissues. RTKN overexpression in GC cells inhibited apoptosis, which was dependent on Rho activity and NF-κB activation. 22, 24 p53, an important tumor suppressor located at 17pl3.1, has multiple biological functions in regulating cell cycle, inhibiting cell apoptosis, and maintaining genome stability via regulating the transcription of >150 target genes. 25, 26 It has been known that loss of function of the p53 gene plays a central role in the development of cancers. Mutations in the p53 gene are the most common genetic alterations and have been reported in various human cancers including GC. [27] [28] [29] The acetylation levels of p53 correlate with the activation and stabilization of p53. 30 In the current study, we confirmed the upregulation of RTKN in GC tissues, explored the association of RTKN expression with the aggressive characteristics and survival properties of GC patients, and investigated the functions of RTKN in GC cell proliferation, cell cycle arrest, and apoptosis. Besides, we explored that the p53 signaling pathway may be involved in the biological functions of RTKN in GC cells. Our data suggest that RTKN may be an effective oncogene and a therapeutic target for GC.
Materials and methods gC tissue microarray
A tissue microarray (Cat#: HStm-A180Su-09, Shanghai Outdo Biotech, Shanghai, China) with 90 matched pairs of primary GC samples and adjacent gastric tissues was applied to evaluate the expression and clinical relevance of RTKN. Among these samples, one paired tumor and adjacent normal tissues were excluded due to incomplete information of the tissues. The core diameter on this tissue microarray was 1.5 mm.
immunohistochemical staining
The sections were deparaffinized in xylene and rehydrated in ethanol, and then heated in 0.01 M citrate buffer (pH 6.0) by autoclave for 20 minutes. Subsequently, to inactivate endogenous peroxidases, the sections were incubated with 0.3% hydrogen peroxide for 30 minutes. After incubation with 10% normal goat serum to block nonspecific binding sites, the sections were probed with anti-RTKN (Abcam, Cambridge, MA, USA) overnight at 4°C, and then incubated with horseradish peroxidase (HRP)-conjugated secondary antibody for 1 hour at room temperature. Finally, the sections were stained with the 3,3′-diaminobenzidine solution (Vector Laboratories, Burlingame, CA, USA) and counterstained with hematoxylin. The specimens were divided into RTKN high-expression group (≥25% of tumor cells were positively stained) and lowexpression group (<25% of tumor cells were positively stained).
Cell culture
Human GC cell lines MKN-45, SGC-7901, MGC-803, and AGS were purchased from Cell Bank of Chinese Academy of Science (Shanghai, China). Cells were cultured and maintained in RPMI 1640 containing 10% (v/v) fetal bovine serum, 100 IU/mL penicillin, and 100 µg/mL streptomycin in a humidified atmosphere of 5% CO 2 in air at 37°C.
Reverse transcription and real-time PCR
Total RNA was extracted from specimens or culture cells with Trizol reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed to complementary DNA with oligo (dT) primers. Real-time PCR was then performed with the genespecific primers and SYBR Green Master Mixes (Thermo Fisher Scientific, Waltham, MA, USA) on real-time PCR system (Thermo Fisher Scientific). The relative expression mRNA levels were normalized to GADPH expression. All primers were designed with Primer Premier 6 Software and are listed in Table 1 . Table 1 Primer pairs used for real-time PCR
Gene
Primers (forward/reverse) RTKN 5′-gCCgCTgCTTaCTaTTgC-3′ and 5′-gTgCTTCCCgaCTTTCTg-3′ HDAC1 5′-gCTCCaCaTCagTCCTTCC-3′ and 5′-ggTCgTCTTCgTCCTCaTC-3′ HDAC2 5′-aggCaaaTaCTaTgCTgTC-3′ and 5′-TgaaaCaaCCCagTCTaTC-3′ HDAC3 5′-CgggaTggCaTTgaTgaC-3′ and 5′-gggCaaCaTTTCggaCag-3′ HDAC8 5′-CTggTCCCggTTTaTaTC-3′ and 5′-CgTCTTCTaCaCCaTCTC-3′ p53 5′-gTgagggaTgTTTgggagaTg-3′ and 5′-CCTggTTagTaCggTgaagTg-3′ P21 5′-TagCagCggaaCaaggag-3′ and 5′-aaaCgggaaCCaggaCaC-3′ Bax 5′-CTgagCgagTgTCTCaag-3′ and 5′-CagCCCaTgaTggTTCTg-3′ PUMA 5′-aTgggaCTCCTgCCCTTaC-3′ and 5′-TCCCTCTCCTggCTTCTTg-3′ GAPDH 5′-aaTCCCaTCaCCaTCTTC-3′ and 5′-aggCTgTTgTCaTaCTTC-3′ 
Manipulation of RTKn expression by lentivirus
shRNA oligos targeting RTKN (shRTKN#1, CCGGGA-AC T G C G G T TAG AG C T G TAT C T C G AG ATAC -AGCTCTAACCGCAGTTCTTTTTC; shRTKN #2, CCGGGAAGCAGTGCTGTGATGAAATCTCGAGA-TTTCATCACAGCACTGCTTCTTTTTC; and shRTKN#3, CCGGAAGAACCCTTGGAGCAAACATCTCGAGAT-GTTTGCTCCAAGGGTTCTTTTTTTC) were annealed and cloned into AgeI-and EcoRI-digested pLKO.1 (Addgene, Cambridge, MA, USA). The full-length human RTKN was cloned into pLVX-puro (Clontech, Palo Alto, CA, USA). The lentivirus of shRTKN, control shRNA (shNC), pLVX-RTKN (OE), or pLVX-puro (Vector) was produced in 293 T cells along with packaging plasmids, psPAX2 and pMD2.G.
siRna
HDAC1 siRNA duplex (siHDAC1, 5′-GGAAGAGUUCUC-CGAUUCU-3′) and control scrambled siRNA duplex (siNC, 5′-CCAUUCCGAUCCUGAUCCG-3′) were synthesized by Genepharma (Shanghai, China). siRNAs were transfected into cells following the manufacturer's instructions of Lipofectamine 2000 (Invitrogen). Cell cycle and apoptosis assays MKN-45 and SGC-7901 cells were treated as indicated. At 48 hours after treatment, the cells were harvested, washed with PBS, and proceeded to cell cycle and apoptosis assays. For cell cycle analysis, the cells were fixed in ethanol at −20°C overnight, washed with PBS, and stained with propidium iodide (PI, Sigma, St. Louis, MO, USA) at 37°C for 30 minutes. The cell cycle distribution was analyzed by using flow cytometry (BD Biosciences, Franklin Lakes, NJ, USA). For cell apoptosis analysis, cells were stained with Annexin V-fluorescein isothiocyanate (FITC) apoptosis detection kit (Beyotime), and apoptotic rates were also analyzed by using flow cytometry (BD Biosciences).
Cell proliferation assay
growth of cells in athymic nude mice and tumor size determination SGC-7901 cells stably transduced with shNC or shRTKN were established by puromycin selection. Twelve male athymic nude mice (4-6 weeks old) were randomly divided into two groups (six mice/group), and shNC and shRTKN cells were subcutaneously injected to the two groups of mice, respectively (2×10 6 cells per mouse). The tumor size was measured every 3 days after tumor formation (around 7-14 days). And 46 days later, the mice were sacrificed, and the tumors were collected and weighted on a digital balance.
Bioinformatics analysis
The microarray data were downloaded from The Cancer Genome Atlas website (TCGA, https://cancergenome.nih. gov/) for the GC project (Access id: TCGA-STAD-expHiSeq). RTKN expression was compared between GC tissues (n=249) and normal gastric mucosa (n=33). Gene set enrichment analysis (GSEA) was conducted as previously described based on TCGA dataset with the GSEA Software version 2.0 from the Broad Institute at MIT. 
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sun et al logical features were assessed using the Fisher's exact test. Kaplan-Meier survival and log-rank analysis were done to determine the association between RTKN expression and overall survival of GC patients. Two-tailed Student's t-test was used to compare results between two groups, while oneway ANOVA followed by Dunnett's multiple comparison was used to compare among three or more groups. P<0.05 was considered significantly different.
Ethics approval and consent to participate
The use of human tissue microarray was approved by Ethics Committee of Putuo Hospital (Shanghai, China) in accordance with the Declaration of Helsinki. The animal experiments were approved by the Animal Research Committee in Putuo Hospital, Shanghai University of Traditional Chinese Medicine, and performed following the guidelines for the Care and Use of Experimental Animals of Shanghai University of Traditional Chinese Medicine.
Results

Upregulated RTKn expression correlated with poor prognosis of gC patients
We first analyzed RTKN expression using TGGA GC dataset, microarray data from ArrayExpress (Access id: TCGA-STAD-exp-HiSeq). As a result, RTKN mRNA expression was significantly higher in GC tissues than in normal gastric mucosa (P<0.0001, Figure 1A) . Immunohistochemistry analysis in a GC tissue microarray that contains 89 pairs of GC tissues and adjacent normal tissues also indicated the upregulated RTKN expression in GC tissues. Further, the 89 GC patients were divided into two groups: RTKN high group (n=55) and RTKN low group (n=34; Figure 1B) , and the association between RTKN expression levels and clinical characteristics was assessed. Notably, RTKN overexpression was strongly associated with tumor size (P=0.0265), TNM stage (P=0.0162), and lymph-node metastasis (P=0.0010; Table 2 ). Kaplan-Meier analysis showed that upregulated RTKN expression was shNC or shRTKN were injected into athymic nude mice respectively, and tumor volumes were measured for 46 days. The xenografts of shRTKN group grew slower than the shNC tumors in mice ( Figure 2G ). At 46 days after inoculation, the size and the weight of shRTKN group were less than half of the shNC tumors ( Figure 2H, I ). These data indicated that downregulation of RTKN inhibited tumor growth in nude mice.
RTKn shRna arrested g0/g1 cell cycle transition and induced apoptosis in gC cells
To explore how RTKN shRNA inhibited proliferation, we investigated the effects of RTKN on cell cycle and cell apoptosis. The increment of G0/G1-phase cells and the reduction of S-phase cells were observed in MKN-45 and SGC-7901 cells transduced with shRTKN when compared with those transduced with shNC ( Figure 3A , B). The protein levels of cell cycle-related proteins, CyclinD1 and PCNA, were also reduced by RTKN shRNA ( Figure 3C , D). As indicated by Annexin V-FITC/PI staining assay, knockdown of RTKN significantly induced cell apoptosis compared with shNC ( Figure 3E, F) . On the contrary, the levels of ATP and lactate dehydrogenase were reduced when RTKN expression was knocked down ( Figure S2 ).
effects of RTKn shRna on the p53 pathway
We then performed GSEA to identify RTKN-associated pathways based on TCGA GC dataset. The results showed that KEGG p53 pathway was strongly associated with RTKN expression ( Figure 4A ). We further detected the mRNA and protein levels of p53 and several p53 target genes. As illustrated in Figure 4B -E, RTKN shRNA enhanced the transcription and translation of p21, Bax, and PUMA in both GC cell lines, while the total protein and mRNA levels of p53 were not affected by RTKN knockdown. Meanwhile, the p53 acetylation (Lys382 and Ace-p53) was also increased by RTKN shRNA in both GC cell lines (Figure 4D, E) .
A previous study has reported that the anti-apoptosis role of RTKN in GC cells is dependent on the activation of NF-κB. 24 The NF-κB activation may be associated with p53 pathway. 32, 33 We then overexpressed RTKN and inhibited NF-κB with PDTC in SGC-7901 cells. Results showed that PDTC enhanced the transcription and translation of p21, Bax, and PUMA in cells overexpressing RTKN, suggesting correlated with the poor prognosis of GC patients within 5 years ( Figure 1C ).
Downregulation of RTKn inhibited gC cell proliferation
Then, we assessed the mRNA and protein expression levels of RTKN in four GC cells -AGS, MKN-45, SGC-7901, and MGC-803 -by real-time PCR and Western blot ( Figure S1 ). Two cell lines, MKN-45 and SGC-7901, showed higher expression. Then, MKN-45 and SGC-7901 cells were transduced with RTKN shRNAs (shRTKN#1, #2, or #3) or control shRNA (shNC). As shown in Figure 2A , B, shNC had no effects on RTKN protein expression when compared with cells without any treatment (Control). RTKN shRNAs obviously reduced RTKN protein expression in both cells, among which shRTKN#1 had the best knockdown efficiency and was selected for the subsequent assays. Real-time PCR results showed a similar trend of RTKN mRNA expression ( Figure 2C, D) . The effects of RTKN knockdown on cell growth at 12, 24, 48, and 72 hours were assessed by CCK-8 assay. Results showed that RTKN shRNA had proliferation-inhibiting property in MKN-45 and SGC-7901 cells compared with shNC at 24, 48, and72 hours post transduction ( Figure 2E, F) .
RTKn shRna inhibited gC growth in nude mice xenograft model hDaC1 mediated the effect of RTKn in p53 acetylation, cell cycle arrest, and cell apoptosis It has been reported that HDAC Class I members (HDAC1, 2, 3, and 8) are able to deacetylate p53 and downregulate the function of p53. 34 GSEA on TCGA dataset showed a positive correlation between the HDAC Class I pathway and RTKN expression in GC tissues ( Figure 5A ). The mRNA levels of HDAC Class I members were analyzed in MKN-45 and SGC-7901 cells with RTKN knockdown. We found that HDAC1 was decreased the most ( Figure 5B, C) , and we speculated that HDAC1 was involved in the effects of RTKN on p53 acetylation in GC cells. To test this speculation, we overexpressed RTKN and knocked down HDAC1 in SGC-7901 cells. Results showed that RTKN overexpression enhanced HDAC1 expression, but suppressed the p53 acetylation, while HDAC1 knockdown had reverse effects. RTKN overexpression could not affect the p53 acetylation in HDAC1 knockdown cells ( Figure 6A ). The alteration of the three p53 target genes was consistent with the changes of the p53 acetylation ( Figure 6A, B) . Results of flow cytometry analyses showed that HDAC1 knockdown arrested G1/S cell cycle transition and induced apoptosis, which was slightly affected when RTKN was simultaneously overexpressed (Figure 6C, D) . These data indicated that HDAC1 was involved in the functions of RTKN on p53 acetylation, cell cycle arrest, and cell apoptosis in GC cells.
Discussion
RTKN was initially identified as a putative target for Rho.
14 RTKN is overexpressed in GC 22 and bladder cancer. 23 In the present study, consistent with the previous report, 22 clinical data showed that RTKN was highly expressed in GC tissues based on our own cohort and TCGA dataset. More importantly, we firstly revealed the association between RTKN expression levels and tumor size, TNM stage, lymph-node metastasis, and overall survival. Our findings further supported that RTKN may serve as a useful prognosis marker for GC.
The possible functions of RTKN in cancer cells have been studied. RTKN interacts with S100A4 and contributes to invasive growth of MDA-MB-231 breast cancer cells. 21 RTKN overexpression inhibits GC cell apoptosis, which is dependent on Rho activity and NF-κB activation. 22, 24 Here, we found that knockdown of RTKN in GC cells significantly decreased cell proliferation and arrested cells at G0/G1 stage. Further in vivo tumor formation assay suggested that knockdown of RTKN in GC cells hindered the growth of xenografts. In line with the previous studies, 22, 24 downregulation of RTKN stimulated cell apoptosis and impaired mitochondrial function targeting cell cycle-related protein, and NF-κB pathway may be applied for cancer therapy. [35] [36] [37] [38] Thus, RTKN may serve as a potential therapeutic target for GC.
p53 is a key mediator of cell cycle progression, cell apoptosis, and DNA repair. 25, 26 Altered expression and mutation of p53 gene have been reported in various human cancers, such as bladder cancer, hepatocellular carcinoma, and GC. [27] [28] [29] Here, GSEA with TCGA dataset identified that RTKN expression was correlated with the p53 signaling pathway. The acetylation levels of p53 correlate with the activation and stabilization of p53. 30 We, therefore, evaluated the effects of RTKN knockdown on the p53 acetylation, and the expression of p53 target genes, p21, Bax, and PUMA. p21, a cyclin-dependent kinase inhibitor, is known to inhibit G1/S transition. 39 Bax and PUMA, two proapoptotic proteins, promote the apoptosis of GC cells. 40 The results showed that the p53 acetylation, and the mRNA and protein levels of all three p53 target genes were obviously increased by RTKN knockdown. On the contrary, RTKN overexpression in AGS cells, which had a relatively lower level of RTKN, showed opposite effect on the protein levels of p53 acetylation, p21, Bax, and PUMA ( Figure S3 ). Thus, it seems that RTKN performs its biological function through the p53 pathway. The antiapoptosis role of RTKN in GC cells has been suggested to be mediated by NF-κB activation. 24 The association between NF-κB activation and p53 pathway has been studied. 32, 33 Here, we found that the NF-κB inhibitor pyrrolidine dithiocarbamate (PDTC) enhanced the transcription and translation of p21, Bax, and PUMA in cells overexpressing RTKN, suggesting that the p53 pathway was also correlated with NF-κB activation. Our findings further enhance the understanding of the roles and mechanisms of RTKN in gastric tumorigenesis.
Then, we tried to investigate how RTKN regulated the acetylation of p53. HDAC Class I members (HDAC1, 2, 3, and 8) are able to deacetylate p53 and downregulate the function of p53. 34 Here, we revealed a positive correlation between the HDAC Class I pathway and RTKN expression in GC tissues by GSEA. Among the four HDAC Class I members, the most obvious inhibitory effect was found in HDAC1 mRNA expression. We found that RTKN overexpression can hardly rescue the inhibitory influence on cell proliferation, migration, and invasion caused by HDAC1 knockdown. These data suggest that RTKN may serve as a tumor suppressor for GC through regulating HDAC1 expression.
Conclusion
In summary, we demonstrated that RTKN promoted the proliferation through inducing cell cycle progression and inhibiting cell apoptosis in GC cells, and RTKN might exert its biological functions through the HDAC1/p53 pathway. RTKN may serve as an oncogene during gastric tumorigenesis and as a novel target for developing therapeutic approaches to GC treatment, although an in-depth study is required to further validate its therapeutic function. 
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